Without sufficient SCFAs, the gut remains in a constant state of low-grade inflammation and heightened sensitivity
This narrative review critically examines preclinical and clinical evidence on Arthrospira platensis and its bioactive metabolites in conditions involving smooth muscle dysfunction, highlighting methodological strengths and limitations, and outlining future research needs
IDH1 mutations cause significant changes in enzymatic reactions, catalyzing the large-scale conversion of -ketoglutarate (2-KG) to 2-hydroxyglutarate (2-HG), and cause significant changes in the cells metabolic system
Most people who experience side effects notice them within the first one to two weeks of therapy, and many improve as the body adapts to changes in growth hormone and insulin-like growth factor 1 (IGF-1) activity
Similarly, the impact of renal or hepatic impairment on BPC-157 pharmacokinetics remains unexplored, though the peptide's metabolism to amino acids and apparent wide therapeutic window suggest limited risk even with reduced clearance